Core Viewpoint - Dong'e Ejiao is making a significant investment of 1.485 billion yuan to build a health consumer goods industrial park, which is a strategic move to adapt to the trend of younger consumers and the foodification of products in the ejiao industry [2][3]. Investment Details - The total investment of 1.485 billion yuan includes 1.421 billion yuan for fixed assets and 64 million yuan for working capital, indicating a focus on capacity construction for health consumer goods [2][3]. - This investment is the largest single investment in the health consumer sector in recent years, highlighting the company's commitment to scaling production capabilities [3]. Market Trends - The consumer base for ejiao is expanding from "middle-aged women" to "universal health," with younger consumers driving demand for ready-to-eat products [3][5]. - By 2025, ready-to-eat ejiao products are expected to account for over 60% of the market, with 62% of young users preferring "ready-to-eat" formats [3]. Capacity and Financial Position - The construction of the industrial park aims to address the current capacity limitations in health consumer goods, which have been a barrier to rapid market growth for new products [4]. - As of Q3 2025, the company has total assets of 12.749 billion yuan and a low debt ratio of 21.77%, providing a solid financial foundation for the investment [4]. Industry Context - The ejiao industry has undergone significant changes, moving from price wars to value return and from traditional nourishment to consumption upgrades [5][6]. - Dong'e Ejiao holds a dominant market share of 70% in the ejiao block category, indicating a strong competitive position [5]. Policy Support - The national push for high-quality development in traditional Chinese medicine provides a favorable environment for Dong'e Ejiao's expansion into health consumer goods [7]. Challenges Ahead - The construction of the industrial park will take 2-3 years, and the company must ensure that production capacity aligns with rapidly changing market demands [8]. - The health consumer goods sector is highly competitive, requiring innovative product development to meet the needs of younger consumers [8]. - The company needs to enhance its online sales channels and improve operational efficiency to compete effectively in the new retail landscape [8]. Industry Implications - Dong'e Ejiao's strategy serves as a reference for traditional Chinese medicine companies, emphasizing the need for product innovation and industry upgrades to achieve sustainable development [9].

近日，河南省政府办公厅印发《河南省提升中药质量促进中医药产业高质量发展若干政策措施》，以23 条精准举措，为河南省中医药产业高质量发展绘制出清晰蓝图。即日起，河南日报开设"从一株草到一 条链"专栏，记者深入医院、科研院所、田间地头、智能车间，剖析一个院内制剂如何通过现代研发转 化为创新中药，关注一株药材如何凭借科技赋能实现优育优种，探访一家药企如何借力智能制造完成转 型升级……通过系列报道，感受河南省中医药产业高质量发展的脉动。 （来源：河南商报） 【河南中医一附院院内制剂出圈记丨#从一株草到一条链#】#院内制剂是如何炼成的# ...

Investment Rating - The report assigns an "Outperform" rating for the pharmaceutical sector, indicating a positive outlook compared to the broader market [2][4]. Core Insights - The collaboration between Innovent Biologics and Eli Lilly has been upgraded, aiming to create a global innovative ecosystem for drug development in oncology and immunology. This partnership marks their seventh collaboration, enhancing their strategic relationship over more than a decade [2]. - The Chinese government has introduced a high-quality development plan for traditional Chinese medicine (TCM), focusing on improving raw material supply, innovation, and manufacturing capabilities. The plan aims to establish a collaborative development system by 2030, with significant investments in TCM innovation [2]. Summary by Sections Market Performance - The SW Pharmaceutical Biotechnology Index increased by 0.14% during the week of February 2 to February 8, outperforming the CSI 300 Index, which decreased by 1.33%. The Chinese medicine sector saw a notable rise of 2.56% due to new policies, while vaccines and other bioproducts experienced declines [2]. Strategic Collaborations - Innovent Biologics and Eli Lilly's new agreement includes a $350 million upfront payment and potential milestone payments of up to $8.5 billion, along with a tiered sales revenue sharing model for products outside Greater China. This partnership signifies a shift from traditional licensing to deeper integration of technology platforms and R&D systems [2]. Investment Opportunities - The report highlights continued optimism for Chinese innovative drugs entering international markets, particularly in areas such as antibody-drug conjugates (ADCs), dual antibodies, small nucleic acids, and weight-loss medications. Key companies to watch include Innovent Biologics, 3SBio, WuXi AppTec, and others [2].

根据公告内容，公司拟使用自有资金及金融机构回购专项借款，以集中竞价交易方式回购社会公众股 份，预计回购金额区间为 6000 万元至 1.2 亿元，回购价格上限为 23.98 元 / 股，回购期限为董事会审议 通过之日起 12 个月。此次回购股份将用于员工持股计划或股权激励、转换公司可转债，旨在进一步完 善公司治理结构，绑定核心团队利益，同时优化资本结构，增强发展韧性。 公告显示，2026 年 2 月 2 日，步长制药顺利完成首次回购。本次共回购股份 217.6 万股，占公司总股本 的 0.21%，回购价格区间为 16.75 元 / 股至 17.12 元 / 股，累计支付资金 3675.79 万元(不含交易费用)。 值得关注的是，本次实际回购价格显著低于 23.98 元 / 股的价格上限，体现出公司在回购操作中的高效 性与审慎性，实现了资金使用效率的最大化。 在资金保障方面，步长制药已与中国农业银行股份有限公司菏泽牡丹支行签署专项借款合同，获得 1 亿 元 3 年期回购专项贷款，结合公司充裕的自有资金，为后续回购计划的推进提供了充足的资金支持。 回购释放多重积极信号 兼顾短期市值维稳与长期战略发展 近期，步长制 ...

如何将中医药资源优势转化为产业发展优势？如何实现中医药产业转型升级？近日，省政府办公厅印发 《河南省提升中药质量促进中医药产业高质量发展若干政策措施》（以下简称《措施》），针对产业源 头管控、制造升级、创新研发、品牌塑造等全链条环节提出23条具体措施，加快构建现代化中医药全产 业链体系，推动我省中医药产业高质量发展。 构建标准化、规模化产业发展新格局 中药质量的提升，始于种植，成于标准。长久以来，中药材种植标准化程度不高、种质资源保护不足、 质量追溯体系不健全等问题，一直影响中药质量的稳定性。 针对"第一车间"的薄弱环节，《措施》首先将焦点对准了种源保护和生态种植。文件提出，开展中药资 源普查和保护，建立省级中药资源数据库；发展中药材现代种业，以临床价值为导向，开展中药材育种 攻关，选育登记一批道地药材新品种。从源头上确保药材的道地性和高品质。 我省是中药材资源大省，中药材种植面积、产量均居全国前列，2024年中医药产业营收已突破500亿 元，但面临企业规模有限、品牌效应不足的问题。 为改变"有资源，缺拳头产品"的局面，我省将着力培育龙头企业和知名品牌。《措施》明确提出，培育 3—5个年营业收入超过30亿元的 ...

Industry Overview - The "Special Regulations on the Registration Management of Traditional Chinese Medicine" is set to reshape the Chinese medicine industry, with a deadline of July 1, 2026, for compliance [1] - The regulation mandates that any traditional Chinese medicine (TCM) with unclear safety information in its instructions will not be re-registered after three years from its implementation on July 1, 2023 [1] Safety and Quality Concerns - Concerns have been raised about the safety of TCM; however, data shows that TCM accounts for only 12% of adverse drug reactions, compared to 81% for chemical drugs, indicating relative safety [2] - The core purpose of the new regulation is to enhance the safety information in TCM product instructions, promoting high-quality development in the industry [2] Company Responses - Leading companies like Yiling Pharmaceutical and Rongchang Pharmaceutical have proactively updated their product instructions to comply with the new regulations, ensuring clear statements on contraindications, adverse reactions, and precautions [3] - Yiling Pharmaceutical has 17 patented TCM products that have been revised according to regulatory requirements, while Rongchang Pharmaceutical has simplified instructions for better consumer understanding [3] Industry Transformation - The industry is at a crossroads, facing short-term compliance pressures while needing to balance innovation and regulation in the long term [4] - The government encourages high-quality development and innovation in TCM, suggesting that products with clear evidence of safety and efficacy will gain a competitive edge in the market [4] - Although the policy changes may cause short-term challenges, they are expected to lead to healthier industry development by eliminating outdated practices and improving product quality [4]

Core Viewpoint - The implementation of the new regulations on traditional Chinese medicine (TCM) product labeling aims to eliminate the "unclear" status in safety information, enhancing the quality and safety of TCM products in the market [1][2][13]. Regulatory Changes - The new regulations, effective from July 1, 2023, require TCM product holders to manage the entire lifecycle of their products and improve the safety information in their labeling, specifically regarding contraindications, adverse reactions, and precautions [1][2]. - By July 1, 2026, any TCM product with "unclear" safety information will not be eligible for re-registration, emphasizing the urgency for companies to update their product labels [1][2]. Industry Response - Many pharmaceutical companies have begun revising their product labels to comply with the new regulations. For instance, companies like Rongchang Pharmaceutical and Yiling Pharmaceutical have completed revisions for their core products, ensuring clear safety information [11][12]. - The industry is adapting by adjusting procurement strategies to focus on compliant products and gradually reducing the inventory of those with high re-registration risks [14]. Market Observations - Despite the new regulations, some commonly used TCM products still display "unclear" safety information, indicating a gap in compliance that needs to be addressed [7][8]. - Reports indicate that TCM accounts for 12% of adverse drug reaction reports, highlighting the need for clearer safety information to mitigate risks associated with TCM usage [7][13]. Future Outlook - The new regulations are expected to promote a shift in the TCM industry from quantity expansion to quality prioritization, ultimately benefiting public health by providing clearer safety guidelines [13][14]. - The elimination of "unclear" labels is anticipated to enhance consumer confidence in TCM products, reducing the risk of unreasonable medication use [14].

说明书中的"尚不明确"即将成为历史，中成药行业加速"低质"出清。 中国工程院院士张伯礼对此回应，中药相对安全。该规定核心目的是推动中医药产业高质量发展。 近5年国家药品不良反应/事件报告中，中药占12%，化学类药物占81%。 （文章来源：21世纪经济报道） ...

记者 李文璇 报道 以实际行动推动中医药事业传承创新,用履职实效回应群众健康期盼,这是李可建身为山东中医药大学校 长的责任和愿景,更是他身为省政协委员的"行动指南"。 在李可建的推动下,山东中医药大学联合多方共建环渤海中医药概念验证与成果转化中心,构建了覆盖"概 念验证—中试熟化—市场转化"全链条的中医药科技成果转化服务体系,2025年共完成119例知识产权转 化。 除将"名医名方"加速转化为"名药名品"外,推动优质中医药资源下沉也是李可建履职的重要方向。2024 年,他提交《关于提升基层中医药服务能力的建议》,其中"开展中医药特色疗法基层推广培训"被纳入 2025年山东省政府工作报告。 李可建通过学术创新和学校管理让这一愿景"落地生根"。记者了解到,2023年底,山东中医药大学获批设 立国家中医药管理局中医药特色疗法评价推广中心,此后,学校精选20余项易教易学的特色疗法,创新推出 套餐式培训模式,截至2025年底共培训636名基层师资骨干,覆盖479所基层卫生服务机构；同时,牵头成 立"中国基层中医药临床实践研究协作网络",扎实开展基层常见病、多发病的中医药特色疗法推广应 用,2025年遴选80个山东省中医 ...

目前全国2199个县市，包括一些市辖区，共建有3099个紧密型县域医共体。超过40%的县级中医医院牵 头组建了县域医共体。此前，国务院办公厅发布《关于提升中药质量促进中医药产业高质量发展的意 见》，提出在遵循中医药的规律和特点上，利用循证医学等手段，积极促进人用经验向临床证据转化， 并鼓励开展已上市中成药评价研究，提升临床价值证据等级。 1月26日，国家卫健委召开新闻发布会，介绍推广三明医改经验，促进中医药传承创新发展有关情况。 会上，国家中医药局医政司司长孟庆彬介绍，近年来，国家出台一系列政策措施，加快推进县级中医院 高质量发展，同时也鼓励有条件的县级中医医院牵头组建县域医共体，带动提升县域中医药服务能力。 公司方面，据上证报表示， 陇神戎发：公司主要业务为医药产品，医疗产品，保健卫生产品的研究开发；中成药，保健食品，原料 药，少量医药中间体，化学药品的生产和销售。 *免责声明：文章内容仅供参考，不构成投资建议 上证报援引研究机构观点称，强化中药产业链协同，优化产业结构布局，头部企业外延并购节奏有望加 快。在保证质量和临床疗效的基础上，中药新药评审加快，有望推动更多优质中药创新产品快速上市。 *风险提示：股 ...